OraSure Technologies Inc. (NASDAQ:OSUR) CEO Douglas A. Michels sold 25,000 shares of the business’s stock in a transaction on Monday, September 26th. The stock was sold at an average price of $8.22, for a total transaction of $205,500.00. Following the completion of the sale, the chief executive officer now directly owns 756,898 shares in the company, valued at approximately $6,221,701.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
OraSure Technologies Inc. (NASDAQ:OSUR) opened at 8.15 on Thursday. OraSure Technologies Inc. has a 12-month low of $4.40 and a 12-month high of $9.05. The firm has a market capitalization of $453.14 million, a P/E ratio of 38.81 and a beta of 1.25. The firm has a 50 day moving average of $8.03 and a 200 day moving average of $7.23.
OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, August 3rd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. OraSure Technologies had a return on equity of 7.60% and a net margin of 10.08%. The company had revenue of $31.36 million for the quarter, compared to analysts’ expectations of $31.15 million. During the same period last year, the business earned $0.03 EPS. OraSure Technologies’s quarterly revenue was up 3.2% compared to the same quarter last year. On average, analysts forecast that OraSure Technologies Inc. will post $0.27 EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of OSUR. Royal Bank of Canada boosted its position in shares of OraSure Technologies by 9.5% in the second quarter. Royal Bank of Canada now owns 93,182 shares of the company’s stock worth $551,000 after buying an additional 8,067 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of OraSure Technologies by 17.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 219,840 shares of the company’s stock valued at $1,300,000 after buying an additional 33,169 shares during the period. American Century Companies Inc. boosted its position in shares of OraSure Technologies by 58.6% in the second quarter. American Century Companies Inc. now owns 606,623 shares of the company’s stock valued at $3,585,000 after buying an additional 224,212 shares during the period. Numeric Investors LLC bought a new position in shares of OraSure Technologies during the second quarter valued at $1,891,000. Finally, Highbridge Capital Management LLC bought a new position in shares of OraSure Technologies during the second quarter valued at $324,000. Institutional investors own 79.65% of the company’s stock.
A number of analysts have recently commented on the stock. BTIG Research lowered shares of OraSure Technologies from a “buy” rating to a “neutral” rating and set a $8.00 price objective on the stock. in a research report on Monday, September 19th. Jefferies Group restated a “buy” rating and set a $10.00 target price (up from $8.00) on shares of OraSure Technologies in a report on Wednesday, August 31st. TheStreet upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, August 30th. Stephens upgraded shares of OraSure Technologies from an “equal weight” rating to an “overweight” rating in a report on Monday, August 29th. Finally, Raymond James Financial Inc. downgraded shares of OraSure Technologies from an “outperform” rating to a “market perform” rating and set a $8.00 target price on the stock. in a report on Monday, June 13th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $8.58.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.